![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1541305
±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå º¸°í¼ : Ä¡·á À¯Çü, ¾à¹° À¯Çü, Åõ¿© °æ·Î, Áö¿ªº°(2024-2032³â)Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2024-2032 |
±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 12¾ï 950¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 32¾ï 360¸¸ ´Þ·¯¿¡ ´ÞÇØ 2024³âºÎÅÍ 2032³â±îÁö 11.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù.
±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML)Àº ºñÁ¤»óÀûÀÎ ¼¼Æ÷°¡ ºü¸£°Ô Áõ½ÄÇϴ Ŭ·Ð¼º ¾Ç¼º Á¾¾çÀÔ´Ï´Ù. ÁÖ·Î °ñ¼ö¿Í ¹éÇ÷±¸(WBC)¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç ÇǺΠº¯»ö, È£Èí°ï¶õ, ÇÇ·Î, °í¿, üÁß °¨¼Ò, ÀÕ¸ö ÃâÇ÷, ÄÚÇǰ¡ Ư¡ÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â AML Ä¡·á¹ý¿¡´Â ÈÇпä¹ý, ¸é¿ª¿ä¹ý, ºÐÀÚ Ç¥Àû ¿ä¹ý, È£¸£¸ó ¿ä¹ý, ¼ö¼ú µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ÀϹÝÀûÀ¸·Î È¿°ú¸¦ ³ôÀ̰í ÇÕº´ÁõÀ» ÃÖ¼ÒÈÇÏ¸ç ½ÅüÀÇ ¸é¿ª ü°è¸¦ °ÈÇϱâ À§ÇØ Áٱ⼼Æ÷ À̽İú ÇÔ²² »ç¿ëµË´Ï´Ù.
Àü ¼¼°èÀûÀ¸·Î ¹éÇ÷º´ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ¹éÇ÷º´Àº ÁַΠü³» À¯ÀüÀÚ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ ¹ß»ýÇϸç, Ç÷¾× ¼¼Æ÷ »ý»ê ¼öÁØ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â AMLÀº ÀÌ·¯ÇÑ Áúº´¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó º´¿ë¿ä¹ý ¹× Ç¥ÀûÄ¡·áÁ¦°¡ ³Î¸® äÅÃµÇ°í ¾Ï Ä¡·á¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ´ëü ¿ä¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³¼±µÈ ¸é¿ªµ¶¼Ò, ¾ËųÈÁ¦, ´ÜŬ·ÐÇ×ü, ´ÙÁ¦³»¼º Á¶ÀýÁ¦ÀÇ µîÀåµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·áÁ¦´Â Ä¡·á È¿°úÀÇ ¿¬Àå, ´õ ³ôÀº È¿´É, ¹éÇ÷º´ ¼¼Æ÷ÀÇ Á¶±â ¹× Á¤È®ÇÑ ½Äº°, ¾Ï Àç¹ßÀÇ °¡´É¼º °¨¼Ò¸¦ °¡Á®¿É´Ï´Ù. Á¾¾çÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿°ú ±âÁ¸ ÀÇ·á ÀÎÇÁ¶óÀÇ ´ëÆøÀûÀÎ °³¼±°ú °°Àº ´Ù¸¥ ¿äÀε鵵 ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global acute myeloid leukemia therapeutics market size reached US$ 1,209.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,203.6 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032.
Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.
The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, drug type and route of administration.
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-Metabolites
Tyrosine Kinase Inhibitors
Others
Small Molecule Drugs
Biopharmaceuticals
Oral
Injectables
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.